These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 16503809)
1. Individualization of mycophenolate mofetil dose in renal transplant recipients. van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809 [TBL] [Abstract][Full Text] [Related]
2. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Nicholls AJ Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430 [No Abstract] [Full Text] [Related]
4. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Fulton B; Markham A Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168 [TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. van Hest RM; van Gelder T; Vulto AG; Mathot RA Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120 [TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Cox VC; Ensom MH Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908 [TBL] [Abstract][Full Text] [Related]
9. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. van Hest RM; Mathot RA; Pescovitz MD; Gordon R; Mamelok RD; van Gelder T J Am Soc Nephrol; 2006 Mar; 17(3):871-80. PubMed ID: 16452491 [TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil: a unique immunosuppressive agent. Hood KA; Zarembski DG Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. van Gelder T; Le Meur Y; Shaw LM; Oellerich M; DeNofrio D; Holt C; Holt DW; Kaplan B; Kuypers D; Meiser B; Toenshoff B; Mamelok RD Ther Drug Monit; 2006 Apr; 28(2):145-54. PubMed ID: 16628123 [TBL] [Abstract][Full Text] [Related]
12. Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children. Villa M; González R; García-Roca P; Hernández AM; Ortiz L; Castañeda-Hernández G; Medeiros M Proc West Pharmacol Soc; 2011; 54():66-8. PubMed ID: 22423584 [TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation]. Uchida K Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884 [No Abstract] [Full Text] [Related]
15. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834 [TBL] [Abstract][Full Text] [Related]
16. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review. Su VCh; Greanya ED; Ensom MH Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Cattaneo D; Cortinovis M; Baldelli S; Bitto A; Gotti E; Remuzzi G; Perico N Clin J Am Soc Nephrol; 2007 Nov; 2(6):1147-55. PubMed ID: 17928466 [TBL] [Abstract][Full Text] [Related]
18. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644 [TBL] [Abstract][Full Text] [Related]
19. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Deierhoi MH; Kauffman RS; Hudson SL; Barber WH; Curtis JJ; Julian BA; Gaston RS; Laskow DA; Diethelm AG Ann Surg; 1993 May; 217(5):476-82; discussion 482-4. PubMed ID: 8489310 [TBL] [Abstract][Full Text] [Related]
20. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]